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Abstract. This review aims to summarize the body of knowledge available on Zika virus to date. 
A comprehensive review of the scientific literature on Zika virus was performed with the aim to 
stress relevant aspects for healthcare professionals in the non-endemic areas. For several years, 
the Zika virus infection was considered an extremely rare exotic disease with poor clinical 
relevance. However, Zika virus has recently gained the attention of the scientific community and 
public opinion since the virus spread to the Pacific islands and the South America in an 
unprecedented epidemic, and additionally due to the definitive evidence that the infection could 
be complicated by Guillain-Barré syndrome, passed through vertical transmission, and result in 
central nervous system abnormalities (including microcephaly) of the fetus. Studies and scientific 
evidence on the complications associated with Zika virus infection are growing day by day. It is 
advisable that the healthcare professionals working in non-endemic areas maintain full 
awareness on this issue in order to practice proper management of the imported cases of Zika 
virus infection. 
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Introduction. For about 60 years after its first 
isolation, which occurred in 1947 from a rhesus 
monkey in the Zika Forest, Uganda,
1
 the Zika 
virus (ZIKV) infection has been considered 
responsible for an extremely rare exotic disease of 
poor clinical relevance and limited public health 
importance. However, since the virus spread to the 
Pacific islands and the South America, causing an 
unprecedented epidemic, it has received the 
attention of the scientific community along with 
public opinion, due to the definitive evidence that 
the infection is associated with Guillain-Barré 
syndrome (GBS) and, when contracted during 
pregnancy, with microcephaly and other 
abnormalities of the central nervous system of the 
fetus.
2
 
Etiologic Agent. ZIKV is an arbovirus (arthropod 
borne viruses), and it is transmitted by mosquitoes 
of the genus Aedes. It belongs to the family 
Flaviviridae, genus Flavivirus, with little genomic 
divergence from other viruses of the same genus.
3
 
The genome of ZIKV consists of a single-stranded 
positive sense RNA molecule of 10794 kb in 
length, and a single central open reading frame 
encoding for a polyprotein, between two non-
coding regions.
4
 The polyprotein is cleaved into a 
capsid protein, a precursor of the membrane 
protein, a protein for the envelope, and seven non-
structural proteins.
4
 Based on the sequencing of 
the entire genome, two main lineages were 
identified, i.e. the African lineage, further divided 
into two groups (clusters Uganda and Nigeria) and 
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the Asian lineage, recently also called 
Asian/American.
3
 Most of the strains belonging to 
the African lineage were isolated from enzootic 
vectors, whereas the Asian lineage has been 
associated with the major human epidemics 
reported until now.
3
 The strains recently isolated 
in the Americas (Brazil, Puerto Rico, Haiti, 
Guatemala, Suriname) show a rapid and wide 
genetic divergence, probably linked to the spread 
of the virus into an immunologically naïve 
population.
3
 Some authors suggest that the high 
rate of complications of ZIKV infection not 
described previously (namely microcephaly and 
GBS), could be due to the phenotypic variations of 
new strains that have originated from the Asian 
lineage. For example, the new strains could induce 
a higher viremia, fostering the transplacental 
transmission and the generation of the human 
reservoir, or they could manifest a greater 
neurotropism.
3
  
 
Life Cycle, Reservoirs and Transmission Route. 
ZIKV infection is mainly transmitted through a 
vectorial route by the bite of mosquitoes belonging 
to the genus Aedes.
3
 Before it spread to the Pacific 
Islands and the Americas, ZIKV was maintained 
in nature through a sylvatic cycle, which is 
probably still the case in Africa.
5
 In Africa, 
enzootic transmission is prevalent; non-human 
primates are the main reservoirs (maybe with other 
vertebrates such as small mammals, birds, and 
reptiles) and the vectors are various species of 
mosquitoes that proliferate preferably in forests, 
such as Ae. furcifer, Ae. luteocephalus, Ae. 
africanus, Ae. vittatus, Ae. taylori, Ae. dalzieli, Ae. 
hirsutus, Ae. metallicus, Ae. unilinaetus, Mansonia 
uniformis, Anopheles coustani and Culex 
perfuscus.
5,6
 Human cases in this setting are 
sporadic. Conversely, the urban cycle has 
sustained the epidemics reported in Micronesia in 
2007, in French Polynesia in 2013-2014, as well as 
the current outbreak in the Americas.
7-9
 In these 
cases, humans are the main reservoir, whereas the 
vectors are different mosquitoes of the genus 
Aedes, such as Ae. hensilli, Ae. polynesiensis and 
Ae. aegypti that have had (or still have) a role in 
the epidemics in Micronesia,
10
 French Polynesia
11
 
and the Americas,
6
 respectively. Furthermore, 
there is laboratory evidence that Ae. albopictus 
(including the Italian strain) can be a competent 
vector for ZIKV,
12,13
 though less effective than Ae. 
aegypti.
13,14
 To date, Ae. albopictus has been only 
suspected to have played a role in the epidemic 
occurred in Gabon in 2007 when the virus was 
detected both in the serum of febrile individuals 
and in mosquitoes of this species.
15
 In that case, 
the ZIKV strain belonged to the African lineage.
15
  
A growing body of evidence indicates that the 
virus can be transmitted during pregnancy through 
the placenta and within the perinatal period.
16,17
 
Indeed, viral RNA was detected by the Polymerase 
Chain Reaction (PCR) in the amniotic fluid, the 
fetal tissues, and the central nervous system of 
newborns from women who contracted the 
infection in pregnancy.
17,18
 There are a number of 
case reports demonstrating the possibility of 
sexual transmission from an infected male to his 
partners (both female and male), both in the case 
of the symptomatic and asymptomatic disease.
19-21
 
The virus was detected in the sperm up to 24 days 
after infection by the viral isolation technique and 
after 188 days by PCR.
22
 Recently, the first case of 
female-to-male sexual transmission of ZIKV was 
reported in the United States,
23
 and ZIKV RNA 
has been detected in vaginal fluids 3 days after 
symptom onset, and in one case, in cervical mucus 
up to 11 days after symptom onset.
24
 Moreover, 
the virus can potentially be transmitted through 
blood transfusions and other substances of human 
origin (SoHO).
25
 There are also a few cases due to 
laboratory accidents,
26
 and a single report of 
suspected transmission due to a monkey bite.
27
 
Aside from serum, the virus has also been isolated 
from urine, saliva, breast milk and semen; 
although the possibility of transmission through 
saliva, breast milk, and urine has not been 
demonstrated to date.
28-31
 
 
Epidemiology. ZIKV was detected for the first 
time in the blood of a rhesus monkey in 1947 at 
the Yellow Fever Research Institute in Entebbe, 
Uganda, and again in the following year, in the 
vector Ae. africanus.
1
 The diagnosis of the first 
human case dates back to 1954, in Nigeria, during 
the investigation of a jaundice outbreak due to 
Yellow fever.
32
 After its discovery, the circulation 
among humans of ZIKV in various areas of Africa 
and Asia was confirmed by a few case reports and 
some seroprevalence studies.
7,33
 The first large 
outbreak was described in 2007, in the Federal 
State of Yap islands in Micronesia, where ZIKV 
infected about 5,000 people, corresponding to 75% 
of the population.
34
 In Thailand, East Malaysia, 
Cambodia, the Philippines and Indonesia, sporadic 
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cases were reported in the following years.
33
 
Between October 2013 and April 2014, a second 
large outbreak affected French Polynesia, where it 
is estimated that 32,000 people were infected 
(11% of the population).
7
 Subsequently, the virus 
spread in many other Pacific Islands such as the 
Cook Islands, Easter Island and New Caledonia, 
the Solomon Islands and Vanuatu.
33
 At the 
beginning of 2015, ZIKV reached the Americas 
for the first time, where it was first reported in 
Brazil’s northeastern State of Rio Grande do 
Norte,
9
 and in a traveller returning to Italy who 
visited Bahia in the same period.
35
 Briefly, the 
virus has spread throughout most of the Brazilian 
States, causing, as of February 2016, between 
500,000 and 1,500,000 infections, according to 
data from the Brazilian Ministry of Health.
36
 Since 
October 2015, Colombia also began to report 
indigenous cases, followed by many other states of 
the Americas.
37
 Currently the World Health 
Organization indicates the presence of a 
continuous vectorial transmission in 60 countries 
and territories, including most of the states of 
Central and South America, many countries in 
South East Asia, Oceania and the Pacific and, with 
regard to Africa, Cape Verde and more recently, 
Guinea Bissau.
2,38
 In July 2016, several 
autochthonous cases were reported in Florida, 
United States.
39
 The list of countries with current 
autochthonous transmission of ZIKV is available 
on the website of the European Centre for Disease 
Prevention and Control: 
http://ecdc.europa.eu/en/healthtopics/zika_virus_in
fection/zika-outbreak/Pages/Zika-countries-with-
transmission.aspx. 
The risk to be infected while travelling seems 
quite small. According to data from the CDC, in 
USA among 3,335 pregnant women who moved 
to- or lived in areas at risk and were tested for 
ZIKV, only 0.8% tested positive; a positive result 
occurring in 2.9% among those who had at least a 
typical symptom of ZIKV, and 0.3% of those 
which remained asymptomatic.
40
 
 
Clinical Manifestations and Pathogenesis of 
Complications. The infection is asymptomatic in 
about 80% of cases.
8
 The incubation period in 
symptomatic cases is not precisely known. 
According to a systematic review, the median 
incubation period is 5.9 days and 95% of 
individuals develops symptoms 11.2 days after the 
exposure.
41
 According to the European Centre for 
Disease Control and Prevention (ECDC) case 
definition,  exposure in an area with transmission 
of ZIKV within two weeks prior to the onset of 
symptoms is considered epidemiological criteria 
for diagnosis, as the incubation period is likely 
less than 14 days.
42
 The infection acquired 
vectorially or by sexual contact has, in almost all 
cases, a benign course without complications 
leading to resolution of symptoms within a period 
of about two weeks. The most common 
manifestation (90% of cases) is a rash, typically 
macular or maculopapular, often itchy and with 
centrifugal evolution (from the trunk to the 
extremities), that generally lasts 4-5 days (range: 
2-14 days).
7,8,33
 In about 65-70% of cases, the rash 
may be preceded by 1-4 days of fatigue and fever 
(generally lower than 38 degrees) for maximum 7 
days.
7,43
 The third most frequent symptom is 
arthralgia (65% of cases), eventually associated in 
20-45% of cases with periarticular edema (hands 
and feet, and less frequently knees and wrists), 
which generally persist for a week (up to a 
month).
7
 Bilateral, not purulent conjunctival 
injection may occur in approximately 55-60% of 
cases, and it typically resolves in 1-2 weeks.
7,8
 
Other manifestations include headache, myalgia, 
and retro-orbital ocular pain. In a case series of 
Brazilian pregnant women with ZIKV infection, 
localized or generalized lymphadenopathy was 
found to be a relatively common clinical 
manifestation (40% of cases), whereas it was 
reported in only 15% of cases during the French 
Polynesia outbreak.
7 
Some authors speculate that the high 
phenotypic variation rate of the strains belonging 
to the Asian lineage isolated in the Americas could 
result in infections characterized by a greater 
neurotropism or a higher viremia, thus fostering 
the transplacental transmission.
3
 Two different 
mechanisms were hypothesized to explain the 
pathogenesis of neurological complications and 
the congenital infection: a direct viral damage and 
an immune-mediated mechanism.
44
 Most of the 
studies conducted so far have investigated the 
former. Studies in animal models (rat) showed that 
ZIKV is extremely neurotropic 
45
 and that it could 
be transmitted through the placenta, inducing 
growth retardation, fetal death, placental damage, 
apoptosis of neural progenitor cells, and impaired 
neural proliferation and development in affected 
fetus.
46-48
 Concerning the immune-mediated 
hypothesis, only slight differences in cytokine 
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levels between acute and convalescent samples 
have been observed in a small cohort of patients.
49
 
Another interesting in vitro observation is that 
plasma immune to virus (DENV) was able to 
enhance ZIKV infection probably through a 
mechanism of antibody dependent enhancement 
(ADE).
50
 According to the ADE mechanism, 
which has been hypothesized for DENV, 
antibodies generated during a primary infection 
with DENV will not be of sufficient concentration 
or avidity to neutralize a secondary infection with 
DENV of a different serotype, however, they 
might still opsonize the secondary virus and thus 
drive higher viral loads.
50
 This observation 
suggests that subjects with previous DENV 
immunity could have more severe ZIKV clinical 
manifestations or increased risk of transplacental 
transmission compared with subjects without 
previous DENV infection. 
The correlation between ZIKV infection and 
GBS was observed for the first time in 2013-2014 
during the ZIKV outbreak in French Polynesia. 
The outbreak registered 42 cases in 4 months, 
compared to an average of 5 cases per year before 
2013.
29
 A study, reporting data from French 
Polynesia epidemic, showed that the risk of 
developing GBS after ZIKV infection is around 
2.4 per 10,000 infections Zika virus, similar to the 
risk following a Campylobacter jejuni infection.
43
 
The appearance of GBS occurred after a period 
ranging from 2 to 23 days (median 6 days) after 
the onset of the symptoms of infection.
7
 The 
typical electromyography pattern found in these 
patients was characterized by acute motor axonal 
neuropathy, without the ganglioside antibodies 
that are characteristic of this condition.
51
 At 
present, in addition to French Polynesia, 12 other 
countries affected by a ZIKV epidemic reported at 
least one case of GBS in patients with recent 
infection, and 8 reported a significant increase 
compared to previous years.
52
 In particular, in 
Brazil from January to November 2015 1,708 
cases were registered, corresponding to an 
increase which varied among the states ranging 
from +526.7% (Alagoas) to +60.9% (Rio de 
Janeiro).
53
 
The correlation between ZIKV and 
microcephaly and other damages due to congenital 
infection was first observed in Brazil. In October 
2015, about seven months after the identification 
of the first cases of ZIKV in the northeast of 
Brazil, the Ministry of Health of Brazil reported an 
unusual increase in cases of microcephaly in the 
states of Pernambuco, Paraiba and Rio Grande do 
Norte, with an evident geographical overlap with 
the epidemic of ZIKV.
54
 
In November 2015, in the state of Paraiba, 
ZIKV RNA was detected in the amniotic fluid of 
two women whose fetus had an ultrasound 
diagnosis of microcephaly.
55
 These findings 
induced the Brazilian Ministry of Health, the 
Centers for Disease Control (CDC), and the ECDC 
to issue  specific alerts on the possible association 
of microcephaly and ZIKV infection.
56,57
 On 
February 1, 2016, following the rise in cases of 
microcephaly and GBS in the areas of ZIKV 
spread, the WHO declared ZIKV a Public Health 
Emergency of International Concern.
58
 An 
increase of 20-times in the frequency of 
microcephaly (20 cases per 10,000 live births) was 
found by comparing the historical statistics of this 
disorder in Brazil with those of 2015.
59
 On the 
other hand, current incidence of microcephaly in 
Brazil could be partially overestimated due to a 
previous under-diagnosis bias and a new 
surveillance protocol, which may have a higher 
sensitivity in detecting cases.
59,60
  Between 
October 2015 and June 30, 2016, Brazil reported 
8,165 suspected cases of microcephaly and other 
nervous system disorders suggestive of congenital 
infection.
38
 Of these, 1,638 are confirmed cases of 
microcephaly, 270 of which have been laboratory-
confirmed for ZIKV infection.
38
 An increase in 
cases of microcephaly has been found 
retrospectively also in French Polynesia after the 
epidemic of 2013-2014.
61
 A retrospective study, 
based on a mathematical model and on data 
collected in French Polynesia, concluded that the 
risk of microcephaly was 1% for newborns of 
women who contracted the infection during the 
pregnancy, and the most dangerous period was the 
first trimester of gestation.
61
 According to a 
second mathematical model built on Brazilian 
data, microcephaly could complicate from 0.88%-
13.2% of pregnancies when the woman is infected 
in the first trimester.
62
 
An observational study in Brazil reported fetal 
abnormalities in 29% (12 of 42) of the pregnant 
women infected with ZIKV, and in none of the 12 
pregnant women who tested negative.
63
 The 
anomalies included fetal deaths at 36 and 38 
weeks of gestation (2 foetuses), intrauterine 
growth restriction (IUGR) with or without 
microcephaly (5), ventricular calcifications or 
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other disorders of the central nervous system (7 
fetuses), abnormalities of the amniotic fluid 
volume, or the brain or umbilical artery flow (7 
fetuses).
63
 
In addition to Brazil and French Polynesia, 
several other countries reported autochthonous 
(Colombia, Cape Verde, El Salvador, French 
Guiana, Marshall Islands, Martinique, Panama, 
Puerto Rico) or imported cases (USA, Spain, 
Slovenia, all in women who had travelled in 
Central and South America) of malformations of 
the central nervous system due to ZIKV congenital 
infection.
38
 Clinical data on infants with 
congenital infection are severe. A study conducted 
in the state of Pernambuco analysed 23 babies 
with microcephaly whose mothers reported 
symptoms compatible with ZIKV infection in the 
first or second trimester.
64
 Seven underwent 
lumbar puncture with detection of IgM anti ZIKV 
in the cerebrospinal fluid. All the children had 
significant severe brain abnormalities noted at the 
CT scan, such as deficiency in brain development, 
brain calcifications (mainly in the corticomedullar 
junction), global hypogyration of the cerebral 
cortex, white matter abnormalities, and significant 
ventriculomegaly.
64
 Moreover, almost a third of 
infants with microcephaly related to ZIKV 
congenital infection had ocular abnormalities, such 
as pigment accumulation in the retina and 
chorioretinal atrophy, abnormalities of the optic 
nerve, bilateral coloboma of the iris, and lens 
subluxation.
65
 
Reports of other severe or life-threatening 
events are exceptional and almost always limited 
to patients with extreme age or comorbidities. 
Among those, there are 4 cases of neuroinvasive 
disease (a case of meningoencephalitis in an 
elderly,
66
 a case of myelitis in a child,
67
 two cases 
of encephalopathy
68
) and two fatal cases in 
patients with severe comorbidities (a child with 
sickle cell disease 
69
 and a man with alcoholism, 
systemic lupus erythematosus, and rheumatoid 
arthritis in chronic treatment with 
corticosteroids
70
). 
 
Diagnosis. The diagnosis is based on serological 
and molecular tests, in addition to clinical and 
epidemiological criteria. The differential diagnosis 
of ZIKV infection may be challenging since signs 
and symptoms are nonspecific and mimic other 
infections and in particular other arbovirosis such 
as dengue and chikungunya which have similar 
clinical presentation and epidemiological 
distribution.
71,72
 Moreover the accuracy of the 
serological tests for ZIKV, including the reference 
test of neutralization, is burdened by a high degree 
of cross-reactions with other flaviviruses.
19,72,73
  
Furthermore, individuals with previous 
infections or immunizations by flavivirus may 
show the "antigenic original sin" phenomenon, i.e. 
they can present a specific antibody response to 
the virus which is responsible for the previous 
infection rather than to the current one.
74
 A 
commercial ELISA test that uses the NS1 antigen 
of ZIKV shows good performance, including in 
terms of specificity.
75
 IgG seroconversion occurs, 
on average, 9 days after the onset of symptoms, 
whereas the IgM may appear 4-5 days after the 
onset.
41
 
With regard to the virological testing, PCR is 
the most used technique. PCR remains positive in 
serum in the first few days of symptoms (usually 
<7 days).
76
 The persistence of viral RNA in saliva 
is similar, although some studies reported that it 
can last up to one month.
29
 In urine, the 
persistence has been demonstrated up to 10-20 
days after manifestation.
76,77
 A recent study 
showed that ZIKV RNA may be detected by PCR 
in whole blood for a longer period than in serum 
and urine (up to 2 months post-symptom onset).
78
 
In one case, a pregnant woman (whose fetus had 
major malformations and congenital ZIKV 
infection) was still viremic at both 4 and 10 weeks 
after the onset of symptoms, suggesting a longer-
lasting viremia in pregnant women.
79
 
In the presence of a laboratory confirmed 
diagnosis during pregnancy and / or 
ultrasonographic evidence of fetal damage 
suggestive for fetal infection, PCR testing for 
ZIKV on amniotic fluid can be performed through 
amniocentesis.
17
 Some experts recommended, 
similarly to other infections in the TORCH group, 
waiting until at least 21 weeks of gestation and 6 
weeks after the onset of symptoms in the mother 
before performing amniocentesis.
80
 The case 
definition of ZIKV according to the ECDC is 
reported in Table 1. 
 
Clinical Management of Pregnant Women. 
Several institutions, like the CDC and ECDC, 
advise pregnant women against travelling to areas 
where the transmission of ZIKV is reported.
38,81
 If 
the travel is indispensable, the woman should pay 
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attention to the prevention of insect bites, especially during the day, using icaridin or DEET  
 
Table 1: Case definition for surveillance of Zika virus infection according to the European Centre for Disease Control and Prevention.  
Available at: http://ecdc.europa.eu/en/healthtopics/zika_virus_infection/patient-case-management/Pages/case-
definition.aspx?preview=yes&pdf=yes#sthash.WAzTC7zm.dpuf  
Classification  
 
 
 
Probable case  
 A person meeting the clinical criteria and the epidemiological criteria. 
 A person meeting the laboratory criteria for a probable case 
Confirmed case  
 A person meeting the laboratory criteria for a confirmed case 
Clinical criteria A person presenting with a rash, with or without fever and at least 1 of the following signs and symptoms:  
 Arthralgia or  
 Myalgia or  
 Non-purulent conjunctivitis/hyperaemia 
Laboratory criteria Laboratory criteria for a probable case:  
 Detection of Zika specific IgM antibodies in serum    
Laboratory criteria for a confirmed case (at least 1 of the following):  
 Detection of Zika virus nucleic acid in a clinical specimen 
 Detection of Zika virus antigen in a clinical specimen 
 Isolation of Zika virus from a clinical specimen;  
 Detection of Zika virus specific IgM antibodies in serum sample(s) and confirmation by 
neutralization test 
 Seroconversion or four-fold increase in the titer of Zika specific antibodies in paired serum samples  
Epidemiological criteria    History of exposure in an area with transmission of Zika virus within two weeks prior to onset of 
symptoms or 
 Sexual contact with a male having been confirmed with a Zika virus infection in the past four weeks 
or 
 Sexual contact with a male who had been in an area with Zika virus transmission in the past four 
weeks 
 A list of Zika affected areas is kept updated on the ECDC website: 
http://ecdc.europa.eu/en/healthtopics/zika_virus_infection/zika-outbreak/Pages/Zika-countries-with-
transmission.aspx  
 
based products.
82
 Both symptomatic and 
asymptomatic pregnant women exposed to the risk 
of infection (those returning from areas where 
transmission of Zika virus is known to occur or 
those who have had sex with males returning from 
areas at risk), should undergo a laboratory test for 
Zika.
83
 Several flow charts for testing pregnant 
women have been proposed.
80,83-85
 In general, the 
screening test to be used for pregnant should be 
selected according to the presence or absence of 
symptoms and the time elapsed since the potential 
exposure. Given the kinetics of the viro-
immunological markers of infection, it is 
worthwhile to use both serological tests and PCR 
on serum, saliva, and urine if the tests are 
performed within one month from the onset of 
symptoms or since the last exposure.
76
 After more 
than one month has passed, serology alone may be 
sufficient, though the long duration of viremia in 
pregnant women could support the use of PCR on 
serum even after a longer period has elapsed. It 
should be noted that the IgM might be negative 
even in the case of recent infection,
84
 probably due 
to the "antigenic original sin" phenomenon.
74,86
 In 
these cases, the diagnosis is based on positivity of  
IgG and PCR.
84
 In the presence of a positive test 
for ZIKV, the woman should undergo an obstetric 
ultrasound follow-up every 3-4 weeks.
83
 The 
option to perform amniocentesis in order to detect 
viral RNA by PCR,
83
 mentioned previously, 
should be considered and discussed with the 
woman, even though data are not present on the 
sensitivity of this technique or on its prognostic 
value in case of a positive result (i.e. it’s unknown 
if positive PCR necessarily lead to fetal and / or 
neonatal disease). Moreover, the presence of 
microcephaly cannot be accurately assessed with 
ultrasounds before the 3rd trimester of 
pregnancy.
80
 Newborns from ZIKV infected 
women should undergo strict neonatology and 
pediatric controls, including serological and 
molecular testing for ZIKV.
83,84,87
 
A pathological evaluation of fetal tissue 
specimens (e.g., placenta and umbilical cord) may 
be used to establish the presence of maternal Zika 
virus infection and can provide a definitive 
diagnosis for pregnant women with a ZIKV 
infection whose serology results were inconclusive 
due to possible cross reactions with other 
flaviviruses.
83
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Therapy and Vaccine. No therapies are available 
to date. The epidemiological and clinical 
experience obtained during the current outbreak 
makes the development of a ZIKV vaccine a 
global health priority. Promisingly, a recent study 
showed that a single immunization with a plasmid 
DNA vaccine or a purified inactivated virus 
vaccine could provide complete protection against 
ZIKV challenges in susceptible mice.
88
 However, 
the achievement of a ZIKV vaccine for humans 
requires a better insight into ZIKV immunology 
and mechanisms of immune protection. For 
example, the development of a live-attenuated 
vaccine is inadvisable until the link between GBS 
and ZIKV will be elucidated and additional 
complications related to pre-existing flavivirus 
exposure should be deeply probed in order to 
develop an efficient and safe vaccine.
89
  
 
Control Strategies in non-Endemic Area. Much 
of the world’s tropical and sub-tropical regions are 
at risk for further ZIKV spread. In temperate 
zones, such as Europe, the emergence of 
autochthonous cases or small foci is possible 
anywhere competent vectors, basically, 
mosquitoes of Aedes genus, are present. In Europe, 
the presence of Ae. aegypti is currently limited to 
Madeira, the eastern coast of the Black Sea, and 
the Netherlands.
90
 However, Ae. albopictus 
mosquitoes, which are proven competent vector 
for ZIKV,
13
 albeit less efficient than Ae. aegypti, 
are widespread in several countries around the 
Mediterranean basin, especially in Italy.
90
 Ae. 
albopictus was implicated in the autochthonous 
cases of dengue fever reported in 2010 in 
Croatia,
91
 in 2010, 2013, and 2015 in France,
92-94
 
and of chikungunya in Italy in 2007,
95
 in France in 
2014,
96
 and in Spain in 2015.
97
 In non-endemic 
areas, the programs for arthropod-borne disease 
control, including ZIKV, have been based on the 
experience gained in the last decades in 
controlling the transmission of dengue and other 
arboviruses, and they are mainly focused on early 
detection and reporting of imported cases and 
vector control measures
98
 in accordance with 
national strategies. For example, in Italy suspected 
cases must be notified to the Public Health 
Authorities within 12 hours during the period of 
activity of Ae. albopictus (from June to October) 
or within 24 hours during  the rest of the year. In 
the period of vector activity, patients with 
suspected or confirmed diagnosis who are not 
hospitalized, should be advised to remain isolated 
at home.
85
 Public health authorities should 
immediately activate rapid vector control 
measures as soon as imported cases are detected, 
in order to implement pest control methods around 
the residence of the index case and the other sites 
that infected patient visited. In France, where 
sporadic autochthonous cases of arboviruses have 
recurred periodically in the summer months since 
2010, the response includes epidemiological and 
entomological door-to-door surveys around the 
index case residence in order to detect further 
infections by an active case finding, and to guide 
vector control measures (elimination of possible 
larval breeding sites, spraying of deltamethrin) in 
the outbreak areas.
92
 
Despite that the main route of ZIKV 
transmission is via the Aedes mosquitoes, strong 
evidence has been demonstrated that ZIKV can be 
transmitted by sexual contact, including vaginal, 
anal and oral sexual intercourse. Based on the 
available knowledge, the CDC and WHO issued 
guidance papers on precautions to be kept: people 
returning from areas where local transmission of 
Zika virus is known should adopt safer sex 
practices or consider abstinence for at least 8 
weeks upon return, and up to 6 months if the male 
partner is symptomatic; couples planning a 
pregnancy should wait for the same duration 
before attempting to conceive.
99
 Men exposed to 
risks of infection should avoid unprotected sexual 
intercourse for the whole length of the gestation if 
their partner is pregnant.
99,100
  
Moreover, a potential risk of ZIKV 
transmission through SoHO has been identified; 
competent authorities and healthcare professionals 
need to be vigilant regarding the risk of donor-
derived ZIKV transmission. A document issued by 
the ECDC based on previous experiences, such as 
for West Nile Virus, is now available to support 
the implementation of national preparedness plans 
for the safety of SoHO, with respect to ZIKV 
infection, in both affected and non-affected 
area.
101
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